US Therapeutic Area Head – Psychosis, Clinical Research
The Current Status of Drug Development in CNS Disorders: Challenges and Opportunities
Although there is significant unmet need in the treatment of schizophrenia, depression, and dementia, many challenges exist to delivering innovative and effective new therapies to patients and to society in general. A major challenge is the recent trend in the pharmaceutical industry to deinvest from CNS drug development. Research and development of CNS drugs is not only more risky than other disease states, but it is also more costly. Despite this trend, many opportunities may be available as incentives for CNS drug development. These include innovative industry-public-academia-government partnerships to efficiently bring scientific innovation to the clinic and fair and thoughtful legislative and regulatory initiatives to encourage continued investment in the CNS space. Lundbeck has a unique history of dedication to the development of CNS drugs and has actually grown its CNS disease portfolio against the trend of other pharmaceutical companies. New therapies that are being pursued by Lundbeck as well as the field in general will be reviewed and will hopefully portray a new excitement built upon diverse societal efforts that are coming together as new opportunities for treating CNS disorders.
Bruce J. Kinon, M.D., is the US Therapeutic Head, Psychosis, at Lundbeck LLC, the US affiliate of the global pharmaceutical company H. Lundbeck A/S headquartered in Denmark. Lundbeck is engaged in the research and development, production, marketing, and sale of drugs for the treatment of disorders in the central nervous system and is committed to improve the quality of life of people suffering from psychiatric and neurological disorders. Dr. Kinon’s responsibilities include the development of innovative drug treatments for schizophrenia and the effective delivery into clinical practice of new pharmacologic therapies for the psychoses.
Dr. Kinon received his M.D. training at the New York University School of Medicine and completed his residency in psychiatry at the NYU-Bellevue Hospital Medical Center in New York City. He has had a long and productive career in the field of neuropsychopharmacology spanning many years in academic research and practice at the Long Island Jewish-Hillside Medical Center in New York, a NIMH center of schizophrenia research, and in pharmaceutical drug development first at Eli Lilly and Company, where he led in part the development and commercialization of the eminently successful atypical antipsychotic drug Zyprexa and later the development of novel glutamate-based schizophrenia therapies, and more recently now at Lundbeck LLC.
Dr. Kinon is an internationally recognized expert who has contributed significantly to safety and efficacy assessments, outcomes research, global marketing, and comprehensive knowledge of the schizophrenia disease state. He has published extensively in internationally recognized peer-reviewed journals and is an often invited chair or participant in panels at international psychopharmacology scientific congresses.
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.